CAR T Cell Data for Pediatric and Young Adult Patients With Relapsed/Refractory ALL

January 9, 2019
Stephan Grupp, MD, PhD

Stephan Grupp, MD, PhD, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high disease burden.

Stephan Grupp, MD, PhD, director of translational research for the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) with high disease burden.

The primary endpoint of the trial was to put these patients into remission, Grupp says. According to the data, around 82% of patients went into remission. At 12- and 18-month follow-ups, 66% of patients remained in remission.